Tirzepatide 10mg

Overview

Tirzepatide 10mg is a synthetic, modified peptide investigated for its activity at two metabolically relevant G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R).

Also identified in scientific literature by the developmental designation LY3298176, tirzepatide was engineered as a single molecular entity capable of producing agonist activity across both incretin-receptor systems.

This dual-receptor profile distinguishes tirzepatide from compounds that act primarily through GLP-1R alone. Laboratory studies examine how coordinated activation of GIPR and GLP-1R may influence receptor-binding behavior, intracellular cyclic adenosine monophosphate production, glucose-responsive cellular signaling, lipid-associated pathways, pancreatic-cell activity, neuronal communication, and energy-regulation mechanisms.

Tirzepatide has been evaluated in biochemical assays, cultured-cell systems, preclinical animal models, pharmacokinetic studies, and regulated clinical trials. FDA-approved prescription medications containing tirzepatide also exist for specific indications and patient populations.

However, the Tirzepatide 10mg material offered here is an independently supplied research product. It is not Mounjaro®, Zepbound®, or any other approved pharmaceutical formulation. Similarity in molecular identity does not establish pharmaceutical equivalence, sterility, bioavailability, safety, or suitability for administration.

All information provided for this product is intended exclusively for analytical, educational, and laboratory-research purposes.

---

Biochemical Characteristics

Tirzepatide is a synthetic 39-amino-acid peptide designed using a glucose-dependent insulinotropic polypeptide-associated sequence framework. Its modified structure permits agonist activity at both GIPR and GLP-1R.

The molecule incorporates non-native amino-acid substitutions and a C20 fatty-diacid-containing side chain connected through a hydrophilic linker. These modifications were designed to influence receptor activity, reduce enzymatic degradation, promote reversible albumin association, and extend experimental exposure compared with native incretin peptides.

Biochemical characterization may include peptide-identity confirmation, chromatographic purity assessment, molecular-mass verification, GIPR and GLP-1R binding analysis, functional cAMP-response assays, albumin-binding studies, and stability testing under defined laboratory conditions.

• Product Name: Tirzepatide 10mg
• Development Identifier: LY3298176
• Molecular Class: Synthetic dual incretin-receptor peptide agonist
• Primary Research Targets: GIPR and GLP-1R
• Receptor Profile: Dual GIP/GLP-1 receptor agonist
• Peptide Length: 39 amino-acid residues
• Peptide Composition: Modified and lipidated peptide analog
• Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈
• Approximate Molecular Weight: 4,813.5 g/mol
• CAS Number: 2023788-19-2
• Purity: Refer to the batch-specific Certificate of Analysis
• Material State: Lyophilized peptide material
• Quantity: 10mg per vial
• Intended Use: Laboratory research only
• Regulatory Status: This research product is not an FDA-approved drug

The stated molecular formula and molecular weight describe the tirzepatide molecular entity. Actual material composition may vary according to counterion, residual moisture, salt form, and batch-specific manufacturing characteristics.

Researchers should consult the corresponding Certificate of Analysis for definitive information concerning identity, purity, net peptide content, and analytical methodology.

---

Research Applications

Within scientific literature, tirzepatide is evaluated as a dual GIPR and GLP-1R agonist. Its applications include biochemical analysis, receptor-signaling studies, cultured-cell investigations, preclinical models, and comparative incretin research.

Documented laboratory research contexts may include:

• Dual-receptor binding assays examining tirzepatide interaction with GIPR and GLP-1R.
• Receptor-selectivity studies comparing relative affinity, potency, and functional activity across the two incretin-receptor systems.
• Functional signaling assays measuring receptor-mediated cyclic adenosine monophosphate accumulation.
• Intracellular pathway analysis examining protein kinase A, exchange proteins activated by cAMP, ion-channel activity, and downstream transcriptional responses.
• Glucose-responsive cellular models evaluating receptor-mediated signaling under varying experimental glucose conditions.
• Pancreatic islet-cell research examining cellular responses associated with GIPR and GLP-1R activation.
• Adipocyte research evaluating GIPR-associated signaling, lipid storage, substrate utilization, and metabolic activity.
• Neuronal pathway studies examining incretin-receptor signaling in experimental central nervous system models.
• Energy-regulation models investigating food-intake behavior, energy balance, and body-composition-associated pathways in animals.
• Albumin-binding studies evaluating how the fatty-diacid-containing side chain affects protein association and experimental exposure.
• Peptide stability studies examining degradation, oxidation, deamidation, aggregation, and structural integrity.
• Comparative incretin research evaluating tirzepatide alongside native GIP, native GLP-1, single GLP-1R agonists, or other dual-receptor compounds.
• Analytical benchmarking using chromatography, mass spectrometry, peptide mapping, and validated reference materials.

These applications are presented strictly as scientific research contexts. They do not constitute recommendations for clinical use, administration, compounding, or self-experimentation.

---

Pathway / Mechanistic Context

Tirzepatide is studied as a dual agonist of GIPR and GLP-1R. Both receptors belong to the class B family of G protein-coupled receptors and participate in overlapping but distinct incretin-associated signaling networks.

GIP Receptor Context

GIPR is activated naturally by glucose-dependent insulinotropic polypeptide. In compatible experimental systems, receptor activation stimulates Gs-protein signaling, adenylate cyclase activity, and intracellular cAMP accumulation.

GIPR research examines glucose-responsive cellular activity, pancreatic signaling, adipose-tissue biology, lipid handling, energy storage, and communication with other metabolic pathways.

GLP-1 Receptor Context

GLP-1R activation can similarly stimulate adenylate cyclase and increase intracellular cAMP. Downstream pathways may involve protein kinase A, exchange proteins activated by cAMP, ion-channel regulation, and transcriptional responses.

GLP-1R research includes pancreatic cellular signaling, glucose-associated pathways, gastrointestinal communication, neuronal activity, food-intake behavior, and energy-balance regulation.

Combined Dual-Agonist Context

Tirzepatide permits researchers to examine the combined activation of GIPR and GLP-1R using a single modified peptide. Experimental activity may differ from the effects produced by separately administering individual receptor ligands.

The magnitude and nature of observed responses may depend on:

• Relative GIPR and GLP-1R expression
• Ligand concentration
• Receptor-binding affinity
• Intrinsic signaling potency
• Cellular and tissue environment
• Experimental glucose concentration
• Exposure duration
• Albumin concentration
• Peptide stability and purity
• Assay methodology

Tirzepatide has demonstrated different relative activity at GIPR and GLP-1R in certain experimental systems. Receptor behavior may also vary according to the species and cellular model evaluated.

Mechanistic findings involving approved pharmaceutical formulations cannot independently establish the identity, quality, safety, or behavior of an independently supplied research product.

---

Preclinical Research Summary

Early biochemical and cellular investigations characterized tirzepatide as a dual GIPR and GLP-1R agonist. These studies evaluated receptor binding, cAMP signaling, peptide stability, pharmacokinetic behavior, and activity relative to native incretin peptides or single-receptor agonists.

Preclinical animal models examined glucose-associated signaling, pancreatic responses, food-intake behavior, energy balance, body composition, lipid metabolism, and other metabolic endpoints under controlled experimental conditions.

Subsequent regulated clinical trials evaluated sponsor-manufactured tirzepatide in defined populations. These investigations contributed to FDA approval of specific pharmaceutical formulations marketed as Mounjaro® and Zepbound®.

Those approvals apply exclusively to the authorized medications, including their approved manufacturing processes, formulations, strengths, dosage forms, administration routes, quality systems, and labeled indications.

They do not apply to Tirzepatide 10mg offered as a laboratory-research material.

Research involving this product does not establish:

• Pharmaceutical equivalence to Mounjaro® or Zepbound®
• Sterility or suitability for administration
• An appropriate human or veterinary dose
• Human bioavailability or pharmacokinetics
• Clinical safety or effectiveness
• Suitability for diabetes management
• Suitability for weight management
• Suitability for cardiovascular or metabolic conditions
• Compatibility with medications or other compounds
• Short- or long-term safety
• Therapeutic, diagnostic, or preventive value

All product-specific use must remain confined to controlled laboratory, analytical, and non-clinical research environments.

---

Form & Analytical Testing

Tirzepatide 10mg is supplied as a research-grade synthetic peptide in lyophilized material form. Lyophilization may support stability during controlled storage but does not establish sterility, pharmaceutical quality, or suitability for administration.

Applicable analytical methods may include:

• High-Performance Liquid Chromatography — HPLC: Used to evaluate chromatographic purity and detect selected peptide-related impurities.
• Ultra-Performance Liquid Chromatography — UPLC: May provide higher-resolution separation of the principal peptide and selected degradation products.
• Liquid Chromatography–Mass Spectrometry — LC-MS: Used to support peptide identity through molecular-mass and mass-to-charge analysis.
• High-Resolution Mass Spectrometry — HRMS: May be used for more precise molecular-mass confirmation.
• Peptide mapping: Used to support sequence identity and evaluate amino-acid substitutions and side-chain modification.
• Amino-acid analysis: May assist in confirming peptide composition and estimating net peptide content.
• Counterion analysis: Used to identify or quantify acetate, trifluoroacetate, or another associated counterion when applicable.
• Water-content analysis: Used to determine residual moisture contributing to total material mass.
• Residual-solvent testing: Used to evaluate selected solvents potentially remaining from synthesis or processing.
• Stability-indicating analysis: Used to examine oxidation, deamidation, hydrolysis, aggregation, and other degradation pathways.
• Microbial or endotoxin testing: Relevant only when specifically performed and documented for the individual batch.

A reported HPLC purity value does not independently establish net peptide content, sterility, potency, endotoxin status, stability, or pharmaceutical quality.

The presence of 10mg of labeled material does not establish that the vial is suitable for administration. Researchers should review the complete batch-specific Certificate of Analysis and follow applicable institutional procedures for laboratory storage, handling, preparation, documentation, and disposal.

---

Referenced Citations

• Coskun, T., et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism, 18, 3–14. PubMed.
• Frias, J. P., et al. (2018). Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes. The Lancet, 392, 2180–2193.
• Frias, J. P., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. The New England Journal of Medicine, 385, 503–515.
• Rosenstock, J., et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes. The Lancet, 398, 143–155.
• Jastreboff, A. M., et al. (2022). Tirzepatide once weekly for the treatment of obesity. The New England Journal of Medicine, 387, 205–216.
• Willard, F. S., et al. (2020). Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight, 5(17), e140532.
• Nauck, M. A., & D’Alessio, D. A. (2022). Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes. Diabetes, Obesity and Metabolism.
• Samms, R. J., et al. (2020). GIPR function in the central nervous system: Implications and novel mechanisms for GIP-based therapies. Diabetes, 69, 243–253.
• U.S. Food and Drug Administration. Tirzepatide pharmaceutical prescribing and regulatory documentation.

ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL, EDUCATIONAL, AND LABORATORY-RESEARCH PURPOSES ONLY. THEY ARE NOT INTENDED TO PROVIDE MEDICAL OR VETERINARY ADVICE.

---

RUO Disclaimer

Tirzepatide 10mg is intended strictly for laboratory, analytical, and scientific research purposes.

Although tirzepatide is the active ingredient in FDA-approved prescription medications, the research-grade product offered on this website is not Mounjaro®, Zepbound®, or any other approved pharmaceutical formulation.

This material has not been established as pharmaceutically equivalent, bioequivalent, sterile, clinically interchangeable, or suitable for administration. The existence of approved tirzepatide medications does not extend regulatory approval to independently supplied research materials.

This product is not intended for:

• Human consumption or administration
• Veterinary use
• Compounding
• Self-experimentation
• Diabetes management
• Weight management
• Clinical or diagnostic use
• Food, beverage, or cosmetic preparation
• Treatment, mitigation, cure, or prevention of disease
• Substitution for an approved prescription medication

For Laboratory Research Use Only (RUO). Not for human use, medical use, diagnostic use, or veterinary use.